Querfeld, C., Palmer, J., Han, Z., Wu, X., Yuan, Y., Chen, M., . . . Zain, J. Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. Elsevier.
Chicago Style (17th ed.) CitationQuerfeld, Christiane, et al. Phase 1 Trial of Durvalumab (anti–PD-L1) Combined with Lenalidomide in Relapsed/refractory Cutaneous T-cell Lymphoma. Elsevier.
MLA (9th ed.) CitationQuerfeld, Christiane, et al. Phase 1 Trial of Durvalumab (anti–PD-L1) Combined with Lenalidomide in Relapsed/refractory Cutaneous T-cell Lymphoma. Elsevier.
Warning: These citations may not always be 100% accurate.